TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:18
OKYO Pharma Ltd ( OKYO ) https://www.okyopharma.com
1.72USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-30.65%
OKYO
SPY
30.72%
OKYO
0.00%
SPY
112.82%
OKYO
0.00%
SPY
201.04%
OKYO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
38.28
32.83
0.05
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-7.65
0.00
-14.73
-26.40
0.00
-5.88
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
111.86
-572.35
0.00
Other Earnings and Cash Flow Stats:
OKYO Pharma Ltd ( OKYO ) Net Income TTM ($MM) is -5.24
OKYO Pharma Ltd ( OKYO ) Operating Income TTM ($MM) is -6.00
OKYO Pharma Ltd ( OKYO ) Owners' Earnings Annual ($MM) is 0.00
OKYO Pharma Ltd ( OKYO ) Current Price to Owners' Earnings ratio is 0.00
OKYO Pharma Ltd ( OKYO ) EBITDA TTM ($MM) is -5.98
OKYO Pharma Ltd ( OKYO ) EBITDA Margin is 0.00%
Capital Allocation:
OKYO Pharma Ltd ( OKYO ) has paid 0.00 dividends per share and bought back -7.192244 million shares in the past 12 months
OKYO Pharma Ltd ( OKYO ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
OKYO Pharma Ltd ( OKYO ) Interest-bearing Debt ($MM) as of last quarter is 0
OKYO Pharma Ltd ( OKYO ) Annual Working Capital Investments ($MM) are -1
OKYO Pharma Ltd ( OKYO ) Book Value ($MM) as of last quarter is -3
OKYO Pharma Ltd ( OKYO ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
OKYO Pharma Ltd ( OKYO ) has 5 million in cash on hand as of last quarter
OKYO Pharma Ltd ( OKYO ) has 9 million of liabilities due within 12 months, and long term debt 2 as of last quarter
OKYO Pharma Ltd ( OKYO ) has 22 common shares outstanding as of last quarter
OKYO Pharma Ltd ( OKYO ) has 0 million USD of preferred stock value
Academic Scores:
OKYO Pharma Ltd ( OKYO ) Altman Z-Score is -34.59 as of last quarter
OKYO Pharma Ltd ( OKYO ) Piotroski Score is 0.00 as of last quarter
Corporate Governance:
OKYO Pharma Ltd ( OKYO ) largest shareholder is owning shares at 0.00 ($MM) value
John P Brancaccio(an insider) Bought 16670 shares of OKYO Pharma Ltd ( OKYO ) for the amount of $25005.00 on 2023-09-15
33.58% of OKYO Pharma Ltd ( OKYO ) is held by insiders, and 0.37% is held by institutions
OKYO Pharma Ltd ( OKYO ) went public on 2022-05-17
Other OKYO Pharma Ltd ( OKYO ) financial metrics:
FCF:-5.28
Unlevered Free Cash Flow:-12.87
EPS:-0.22
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:191.28
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About OKYO Pharma Ltd ( OKYO ) :
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.